
Elif Buse ÇalışkanUniversity Hospital Essen | UK Essen · Clinic for Neurology
Elif Buse Çalışkan
Doctor of Medicine
About
8
Publications
478
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
21
Citations
Education
November 2020 - July 2021
Universitätsklinikum Augsburg
Field of study
- Medicine
March 2020 - July 2020
Ruprecht-Karls-Universität Heidelberg
Field of study
- Medicine
September 2015 - July 2021
Publications
Publications (8)
Dopamine-based reward and learning mechanisms have been suggested to contribute to placebo effects. However, the exact role of dopaminergic neurotransmission in their generation and maintenance is still unclear. This study aimed to shed light on the causal role of dopamine in establishing positive treatment expectations, as well as on the magnitude...
Introduction
Positive and negative treatment expectations are powerful modulators of health and treatment outcomes. A substantial part of treatment success is due to contextual factors modulating patient's expectations towards a treatment. Consequently, treatment expectations should be a target of therapeutic interventions themselves.
Objectives
T...
Objectives
Infliximab (IFX) is being increasingly used for the treatment of severe manifestations of Behçet syndrome (BS). However, emergence of new manifestations has also been occasionally reported during IFX treatment. We aimed to assess the frequency of new manifestations in our BS patients treated with IFX.
Methods
A chart review was conducte...
Background
Infliximab (IFX) is increasingly used in the management of severe, relapsing or refractory manifestations of Behçet Syndrome (BS). Emergence of de novo manifestations have been reported during IFX treatment, despite efficacy for the initial manifestation that required IFX use ¹ .
Objectives
We aimed to survey a sizeable cohort of BS pat...
Background
Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). TNF inhibitors have been reported to be effective for almost all serious manifestations of BS but data on vascular involvement is still limited.
Objectives
To survey the efficacy and safety of infliximab (IFX) in BS patients with...
Background
Nervous system involvement of Behçet syndrome (neuroBS) is a serious, but infrequent manifestation of Behçet syndrome (BS). Although many BS patients present with signs and symptoms related to the nervous system, several of these are diagnosed with conditions other than neuroBS. The differential diagnosis may be difficult in such patient...